- Home
- VALN
VALN
Valneva SE
as 12-18-2024 12:44pm EST
Valneva SE is a vaccine company focused on developing life-saving vaccines. Its portfolio includes three vaccines for travelers. The segments of the group are Commercialized vaccines which relate to marketed vaccines, the group's vaccines IXIARO/JESPECT, DUKORAL, IXCHIQ; Covid includes development, manufacturing, & distribution related to the COVID-19 vaccine, Vaccine candidates which relate to research and development programs to generate new approvable products to generate future cash flows from product sales through partnering with pharmaceutical companies; & Technologies and services which relate to services and inventions at a commercialization stage. The company generates the majority of its revenue from product sales.
| Founded: | 2012 | Country: | France |
| Employees: | N/A | City: | N/A |
| Market Cap: | 332.0M | IPO Year: | 2021 |
| Target Price: | $18.50 | AVG Volume (30 days): | 30.5K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 2 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.06 | EPS Growth: | N/A |
| 52 Week Low/High: | $3.65 - $10.76 | Next Earning Date: | 11-07-2024 |
| Revenue: | $176,817,979 | Revenue Growth: | -28.98% |
| Revenue Growth (this year): | 24.3% | Revenue Growth (next year): | 16.05% |
Latest Valneva SE News
VALN Breaking Stock News: Dive into VALN Ticker-Specific Updates for Smart Investing
GlobeNewswire
14 days ago
VALNEVA - Declaration of shares and voting rights: November 30, 2024
GlobeNewswire
15 days ago
Valneva Announces Peer-Reviewed Publication on the Global Health and Economic Burden of Chikungunya in The British Medical Journal
GlobeNewswire
16 days ago
Valneva Reports Positive Three-Year Antibody Persistence Data for its Single-Shot Chikungunya Vaccine IXCHIQ®
Zacks
20 days ago
Chikungunya Vaccine Label Extension Call Likely to Support VALN Stock
MT Newswires
22 days ago
Valneva Submits Label Extension Application to US FDA for Chikungunya Vaccine IXCHIQ
GlobeNewswire
22 days ago
Valneva Submits Label Extension Application for its Chikungunya Vaccine, IXCHIQ®, to the U.S. FDA
Simply Wall St.
24 days ago
High Growth Tech Stocks To Explore This November 2024
The Wall Street Journal
a month ago
European Vaccine Makers Under Pressure After Trump Picks RFK Jr to Lead Health Department
Compare VALN vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "VALN Valneva SE - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.